Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 8 von insgesamt 8
- Rekrutierung läuftMulticenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123IndikationenMolekulare Marker
- Rekrutierung läuft
A First – in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3
Molekulare Marker - Rekrutierung läuftA Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/ or Refractory Multiple Myeloma; Studienteil: Expansionsphase
- Rekrutierung läuftPhase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)Target: PRAME
- Rekrutierung läuftA Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
- Rekrutierung läuftFirst-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies
- Rekrutierung läuftA Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumorsIndikationenMolekulare Marker
- Rekrutierung läuftA Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment